Lantern Pharma Achieves Targeted Enrollment for Phase 2 HARMONIC Trial in Japan

Lantern Pharma (NASDAQ: LTRN) has reached a pivotal milestone by completing the targeted enrollment for its Phase 2 HARMONIC clinical trial in Japan ahead of schedule. This trial is specifically designed for never-smoker non-small cell lung cancer (NSCLC) patients who have experienced progression after treatment with tyrosine kinase inhibitors. The enrollment of 10 patients across five sites, including the National Cancer Center Japan, highlights the company's strategic focus on regions with a higher prevalence of this patient demographic, such as Japan and Taiwan, where enrollment continues alongside U.S. sites.

The HARMONIC trial is evaluating the effectiveness of LP-300 in combination with carboplatin and pemetrexed. Preliminary data from U.S. sites have been encouraging, showing an 86% clinical benefit rate, including a durable complete response lasting nearly two years. With the global trial aiming to enroll around 90 patients, these findings could further validate Lantern Pharma's innovative approach to cancer treatment. CEO Panna Sharma emphasized the importance of this achievement, showcasing the company's dedication to using its proprietary RADR(R) platform to fast-track the development of transformative therapies for cancer patients globally.

At the core of Lantern Pharma's success is its RADR(R) platform, which leverages over 100 billion oncology-focused data points and a suite of more than 200 advanced machine learning algorithms. This AI-driven methodology is revolutionizing the oncology drug discovery and development process, enabling the company to assemble a diverse pipeline of therapies targeting various cancer types, with a combined annual market potential surpassing $15 billion USD. The swift enrollment in Japan not only reflects the urgent global demand for innovative cancer treatments but also cements Lantern Pharma's position at the forefront of integrating AI with oncology.

For further details on Lantern Pharma's pioneering efforts and the HARMONIC trial, visit https://ibn.fm/IcDma. Additional updates and news about Lantern Pharma are available in the company's newsroom at https://ibn.fm/LTRN.